risperidone has been researched along with ly 2140023 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP | 1 |
| Brenner, R; Downing, AM; Gomez, JC; Kinon, BJ; Liu, L; Millen, BA; Morozova, MA; Nisenbaum, L; Rayle, TJ; Zhang, L; Zhao, F | 1 |
2 trial(s) available for risperidone and ly 2140023
| Article | Year |
|---|---|
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult | 2013 |
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Topics: Adult; Aged; Amino Acids; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Receptors, Metabotropic Glutamate; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2014 |